BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Zydus Lifesciences Secures US FDA Nod For Prostate Cancer Drug

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Zydus Lifesciences received USFDA approval to produce generic Enzalutamide tablets for prostate cancer. The drug generated $1.4 billion in US sales annually and will be manufactured in Ahmedabad.

Zydus Lifesciences news today

Zydus Lifesciences, one of India’s leading pharmaceutical companies, has secured tentative approval from the US Food and Drug Administration (USFDA) to manufacture generic Enzalutamide tablets. These tablets, in doses of 40 mg and 80 mg, are used to treat patients suffering from castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

ZYDUS LIFESCIENCES LTD

Trade

978.52.00 (0.20 %)

Updated - 13 December 2024
981.45day high
DAY HIGH
955.05day low
DAY LOW
650878
VOLUME (BSE)

Manufacturing approval and production plans

The company has announced that the production of Enzalutamide tablets will take place at its state-of-the-art manufacturing facility located in the Special Economic Zone (SEZ) in Ahmedabad. This approval marks an important milestone for Zydus Lifesciences as it further strengthens its foothold in the global pharmaceutical market, particularly in oncology treatments.

Market potential and competition

Enzalutamide is an androgen receptor inhibitor, which is a crucial treatment for advanced stages of prostate cancer. According to IQVIA data from July 2024, the US market for Enzalutamide tablets (40 mg and 80 mg) is significant, with annual sales of $1,417.2 million. The US FDA's approval provides Zydus with an opportunity to tap into this lucrative market with its generic version, creating potential competition in a field currently dominated by branded drugs.

Zydus Lifesciences' expanding portfolio

Zydus Lifesciences has steadily built an impressive portfolio of generic drugs, with the company now securing 400 approvals from the US FDA. Since it began filing Abbreviated New Drug Applications (ANDAs) in FY 2003-04, Zydus has submitted over 465 ANDAs, positioning itself as a major player in the generic drug industry.

Growing demand for prostate cancer treatments

Prostate cancer is one of the most common cancers affecting men worldwide, with increasing demand for effective treatments. Introducing a more affordable generic version of Enzalutamide in the US market is expected to benefit patients by improving access to life-saving medication. Zydus Lifesciences’ foray into the prostate cancer treatment market with the approval of this drug aligns with global healthcare efforts to meet the rising demand for cancer treatments.

Zydus Lifesciences’ latest US FDA approval signifies the company’s growing expertise in oncology treatments. With the launch of its generic Enzalutamide tablets, the firm is poised to expand its market reach further.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text